124 related articles for article (PubMed ID: 37798437)
1. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.
Benjamin DJ; Shrestha A; Fellman D; Cress RD; Lythgoe MP; Rezazadeh Kalebasty A
Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37798437
[TBL] [Abstract][Full Text] [Related]
2. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
3. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
4. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
6. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer.
Meng MV; Grossfeld GD; Sadetsky N; Mehta SS; Lubeck DP; Carroll PR
Urology; 2002 Sep; 60(3 Suppl 1):7-11; discussion 11-2. PubMed ID: 12231037
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
8. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
9. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
10. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
11. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781
[TBL] [Abstract][Full Text] [Related]
12. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.
Potosky AL; Reeve BB; Clegg LX; Hoffman RM; Stephenson RA; Albertsen PC; Gilliland FD; Stanford JL
J Natl Cancer Inst; 2002 Mar; 94(6):430-7. PubMed ID: 11904315
[TBL] [Abstract][Full Text] [Related]
13. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
14. The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.
Lawrenson R; Obertová Z; Brown C; Fong P; Tyrie L; Scott N; Holmes M
J Cancer; 2014; 5(3):214-20. PubMed ID: 24563676
[TBL] [Abstract][Full Text] [Related]
15. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.
Wang C; Raldow AC; Nickols NG; Nguyen PL; Spratt DE; Dess RT; Yu JB; King CR; Chu FI; Chamie K; Litwin MS; Saigal CS; Reiter RE; Liu ST; Rettig MB; Chang AJ; Steinberg ML; Kupelian PA; Kishan AU
Eur Urol Oncol; 2021 Apr; 4(2):327-330. PubMed ID: 31411981
[TBL] [Abstract][Full Text] [Related]
16. Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
Adv Radiat Oncol; 2022; 7(4):100904. PubMed ID: 35814856
[TBL] [Abstract][Full Text] [Related]
17. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
18. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Broering JM; Cooperberg MR; Carroll PR
J Urol; 2022 Apr; 207(4):832-840. PubMed ID: 34854749
[TBL] [Abstract][Full Text] [Related]
20. Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer.
Wu SY; Fang SC; Hwang OR; Shih HJ; Shao YJ
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
